

WHAT is Biohope?

Biohope is a commercial stage R&D company dedicated to the development of precision medicine IVD tools for chronic inflammatory / autoimmune conditions.

Founded in 2015, Biohope employs 17 professionals in R&D, Medical Affairs, Financial, Legal, Regulatory, IT and Business Development & Licensing.

The company has developed a unique technology, proven in international clinical studies with world-class institutions. Biohope has developed its first product (IMBG-Renal Transplant), and is developing its pipeline in other autoimmune chronic diseases.

Biohope is working with several Companies to market the Immunobiogram© in Europe, North America, and Asia Pacific.

Biohope has won several Entrepreneurship Awards by Spanish Authorities, and has received international recognitions as well.

Mission

Biohope is a biotechnological and IT company that investigates, develops and commercializes unique medical solutions in the field of chronic inflammatory conditions. We help to improve clinical outcomes to facilitate treatment adjustment and personalization of immunosuppressive therapies and generate global research patient and management information.

“Our scientific ambition is to become a worldwide reference in personalize medicine because we provide innovative, first in class, practical solutions that significantly improve clinical outcomes in autoimmune - related conditions with unmet needs, benefitting patients, physicians and health care systems.”

(Isabel Portero, CEO & Founder)

Biohope



Biohope
PRECISION MEDICINE
GIVING HOPE
Immunobiogram®

Technology park – D122 Santiago Grisolia 2, 28760
Tres Cantos (Madrid) – SPAIN
Phone: +34 912 187 043
Email: info@biohope.eu
www.biohope.eu



PRECISION MEDICINE
GIVING HOPE

WHAT do we do?

Provide the first solution to an unmet medical need in the treatment of chronic inflammatory / autoimmune conditions.

Different patients need different drugs.

Currently, immunosuppressant (IS) selection and dosing is done empirically, only based in clinical guidelines, IS pharmacokinetic levels, and IS side effects profile.

Because of that:

- ⌚ Near 50% of patients will suffer the loss of the kidney graft in 10 years.
(deceased-donor kidney transplant, unadjusted)¹
- ⌚ Rejection is the most important cause of graft failure (64%) and it is closely related with the immunosuppressive treatment patients receive²
- ⌚ Patients treated with IS have a higher risk of severe side effects like cancer or opportunistic infections.

In a nutshell, current medication when not based on the patient profile response to IS can lead to increased healthcare costs, a rise in side effects and a worsened prognosis.

Based on our technological platform we apply AI tools to:

- ⌚ Elaborate individual patient reports to improve clinical management.
- ⌚ Generate insights to address patient management strategies.

¹United States Renal Data System. 2017 USRDS annual data report. vol 2 Table 6.4 Trends in 1-, 5-, & 10-year deceased-donor kidney transplant outcomes. <https://www.usrds.org/2017/view/Default.aspx>

²Sellares et al. American Journal of Transplantation 2012; 12: 388-399



HOW do we do it?

Thanks to a combination of biology and data analysis tools.

An innovative and effective IVD product

- ⌚ Evaluates the sensitivity/resistance profile of a patient to a panel of IS.
- ⌚ High precision and robustness.
- ⌚ Simple and useful physician report.

Based on a proven technology

Immunobiogram® has been studied in KIDNEY TRANSPLANT under a comprehensive clinical program, including a multicenter international study.

Immunobiogram® has shown very positive results that have been presented at several international congresses.

Biohope's technology is the cornerstone of our pipeline

- ⌚ Rheumatoid arthritis.
- ⌚ Liver transplant.
- ⌚ Lupus.

WHAT is Immunobiogram® RT?

IMBG is a novel IVD test allowing the selection of the optimal immunosuppressive therapy (combination of drugs / dosage) for each patient.

Which drugs?

Which doses?

- ⌚ Provides an individualized patient response pattern to immunosuppressive medication.
- ⌚ Sensitivity/resistance profile can be determined in each patient for each of the drugs and doses tested.
- ⌚ Allows to identify patients with bad prognosis due to low sensitivity to specific immunosuppressants.
- ⌚ The routinely use of the Immunobiogram® in patients one year after their kidney transplant, may have the potential to reduce the risk of renal graft failure and AEs associated with IMSs, with considerable savings for the NHS.

"With this product the Beneficiary will revolutionize the kidney transplantation market and will become a key player in this system."

(2018 European Commission Report)

imBG_{RT}